At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 867 enrolled
Drug / intervention
IC51 +1 morebiological
Likely dose
IC51 6 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of IC51 vs. JE-VAX as Vaccines for Japanese Encephalitis in Healthy Subjects
In Brief
A Phase 3 clinical trial evaluating IC51 and JE-VAX for Japanese Encephalitis. Completed, enrolled 867 participants.
Detailed Summary
The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged \> or = 18 years
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
Primary CompletionSep 2006
First PostedJan 2008
TodayJul 2026
First PostedJan 30, 2008
Enrollment StartSep 1, 2005
Primary CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.4 years ago
Interventions
IC51biological
IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
JE-VAXbiological
JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28